Amicus Therapeutics Inc.
Amicus Therapeutics Inc. Announces Annual Meeting Outcomes
Summary
Amicus Therapeutics Inc. reported the outcomes of its 2024 Annual Meeting of Stockholders, including the election of new directors, approval of the Amended and Restated 2007 Equity Incentive Plan, ratification of Ernst & Young LLP as the independent registered public accounting firm, and advisory approval of executive compensation. The company also furnished the relevant financial statements and exhibits with this filing.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement